Edwin Perez-Lopez, MD
Family Medicine · Benton, KYNPI 1447272299
Payments from drug & device makers
Across 319 payments — averaging $15.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$788
- Lilly USA, LLC$495
- Pfizer$476
- Boehringer Ingelheim$468
- AstraZeneca$355
- Amgen$288
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,786100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 43 | $788 |
| Lilly USA, LLC | 35 | $495 |
| Pfizer | 44 | $476 |
| Boehringer Ingelheim | 36 | $468 |
| AstraZeneca | 15 | $355 |
| Amgen(2 entities) | 21 | $288 |
| Novo Nordisk | 19 | $283 |
| Johnson & Johnson | 16 | $237 |
| Merck | 16 | $135 |
| GSK | 8 | $122 |
| Ironshore Pharmaceuticals Inc. | 3 | $119 |
| Otsuka America Pharmaceutical, Inc. | 6 | $116 |
| Supernus Pharmaceuticals, Inc. | 5 | $112 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $97 |
| Bayer | 6 | $96 |
| Novartis | 4 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $53 |
| Exact Sciences | 3 | $51 |
| Sumitomo Pharma America, Inc. | 3 | $51 |
| Astellas Pharma US Inc | 2 | $40 |
| Sunovion Pharmaceuticals Inc. | 3 | $36 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Ironwood Pharmaceuticals, Inc | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Amarin Pharma, Inc. | 2 | $24 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Medtronic | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Abbott | 1 | $17 |
| Dexcom, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Collegium Pharmaceutical, Inc. | 1 | $12 |
| Scilex Pharmaceuticals Inc. | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Sanofi Pasteur Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,786 in reported general payments places this provider in the 80th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 402 | $262,567 |
| MounjaroTirzepatide | 143 | $182,515 |
| TrulicityDulaglutide | 146 | $176,196 |
| OzempicSemaglutide | 136 | $151,872 |
| JardianceEmpagliflozin | 95 | $81,489 |
| JanuviaSitagliptin Phosphate | 89 | $74,102 |
| Tresiba Flextouch U-200Insulin Degludec | 47 | $67,245 |
| XareltoRivaroxaban | 85 | $51,632 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 62 | $43,873 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $36,902 |
| EntrestoSacubitril/Valsartan | 32 | $28,680 |
| LinzessLinaclotide | 52 | $27,207 |
| MyrbetriqMirabegron | 68 | $24,221 |
| NuedextaDextromethorphan Hbr/Quinidine | 21 | $23,865 |
| Lupron DepotLeuprolide Acetate | 11 | $23,501 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $495 | $358,711289 claims |
| PfizerEliquis | $476 | $262,567402 claims |
| Novo NordiskOzempic | $283 | $151,872136 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $468 | $113,982148 claims |
| MerckJanuvia, Belsomra | $135 | $81,964115 claims |
| Johnson & JohnsonXarelto, Invokana | $237 | $74,731107 claims |
| AbbVieLinzess, Lupron Depot, Vraylar | $788 | $70,50175 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $355 | $62,78480 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $122 | $57,73566 claims |
| NovartisEntresto | $74 | $28,68032 claims |
| Astellas Pharma US IncMyrbetriq | $40 | $24,22168 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Benton
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
- Jeffrey GreenParis$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.